Type 5 diabetes mellitus: redefining pancreatogenic diabetes through molecular, imaging, and AI-driven evidence

(2025) Type 5 diabetes mellitus: redefining pancreatogenic diabetes through molecular, imaging, and AI-driven evidence. Frontiers in Endocrinology. p. 1749805. ISSN 1664-2392 (Print) 1664-2392 (Electronic) 1664-2392 (Linking)

Full text not available from this repository.

Abstract

BACKGROUND: Type 5 Diabetes Mellitus (T5DM), denoting pancreatogenic diabetes from fibro-inflammatory pancreatic injury, is a distinct yet under-recognised entity. Current WHO and ADA classifications overlook its complex, concurrent endocrine-exocrine failures, contributing to misdiagnosis, treatment gaps, and suboptimal outcomes. OBJECTIVES: This review aims to critically analyze current scientific understanding of the pathogenesis, diagnostic criteria, metabolic consequences, and therapeutic needs of T5DM and suggest a precise framework of medicine that justifies the need for T5DM to be formally recognized as a sub-type of diabetes. METHODS: An integrative review was conducted using recent literature on pancreatic pathophysiology, molecular biomarkers, radiomics, diagnostic imaging, glycemic control technologies, and machine learning. The focus was on the recent literature to elucidate the biological, diagnostic, and treatment aspects of the clinical studies, guidelines, and mechanistic research available from the publications. KEY FINDINGS: T5DM involves loss of insulin and glucagon alongside exocrine pancreatic insufficiency, malnutrition, and significant glycaemic variability. A tiered diagnostic framework-integrating pancreatic imaging, endocrine-exocrine testing, autoimmune exclusion, and emerging biomarkers-enhances accuracy. Management requires coordinated hormonal and enzyme replacement, structured nutritional support, and targeted surveillance for malignancy and micronutrient deficits. Radiomics, quantitative imaging, and AI-driven analytics offer valuable tools for earlier detection, improved risk stratification, and personalised therapy. CONCLUSION: T5DM warrants recognition as a distinct diabetes entity owing to its unique pathophysiology, clinical behaviour, and therapeutic needs. Harmonised diagnostic criteria, validated biomarker and imaging pathways, and multicentre registries are essential to integrate T5DM into global classification systems and advance mechanism-based, personalised care.

Item Type: Article
Keywords: Humans Biomarkers Radiomics *Artificial Intelligence *Diabetes Mellitus/diagnosis AI diagnostics exocrine pancreatic insufficiency pancreatogenic diabetes precision medicine reclassification type 5 diabetes mellitus commercial or financial relationships that could be construed as a potential conflict of interest.
Page Range: p. 1749805
Journal or Publication Title: Frontiers in Endocrinology
Journal Index: Pubmed
Volume: 16
Identification Number: https://doi.org/10.3389/fendo.2025.1749805
ISSN: 1664-2392 (Print) 1664-2392 (Electronic) 1664-2392 (Linking)
Depositing User: خانم ناهید ضیائی
URI: http://eprints.mui.ac.ir/id/eprint/33474

Actions (login required)

View Item View Item